Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc....

Cipher Pharmaceuticals Inc. (TSX: DND) today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three months ended March 31, 2011 ("Q1 2011"). The first quarter of 2011 represents the...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced it will host a conference call for its Q1 2011 financial results and hold an Annual & Special Meeting of Shareholders on Thursday, May 12,...

- Results highlighted by 70% increase in revenue - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, March 9 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and...

- Fourth quarter and year-end financial results to be released March 9, 2011 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Feb. 23 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2010. Q3 2010 Summary --------------- - Net revenue...

- Third quarter financial results to be released October 27, 2010 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 18 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that the U.S. Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-TRAMADOL ER, the Company's extended-release...

Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the 9th Annual BIO Investor Forum, which is being held in San...

Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Rodman & Renshaw Annual Global Investment Conference, which...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2010. Q2 2010 Summary --------------- - Net revenue...

- Second quarter financial results to be released July 28, 2010 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, July 8 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it reached a cumulative sales milestone for Lipofen(R), the Company's fenofibrate product. Achieving this target triggers a US$1.0...

Cipher Pharmaceuticals Inc. (TSX: DND) today commented on the outcome of the appeal by Purdue Pharma Products L.P. of the decision of the United States District Court for the District of Delaware...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced the U.S. Food and Drug Administration ("FDA") has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three months ended March 31, 2010. Q1 2010 Summary --------------- - Total revenue increased...

- First quarter financial results to be released April 23, 2010 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, April 16 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced it will hold its Annual and Special Meeting of Shareholders on Thursday, April 22, 2010 at 4:30 p.m. ET. WHAT: ANNUAL AND SPECIAL MEETING OF...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has reached the enrollment mid-point in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009. Fiscal 2009 Summary -------------------...

- Fourth quarter and year end financial results to be released February 17, 2010 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Feb. 5 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced a final judgment (the "Cipher Judgment") has been entered in favour of Cipher in relation to pending patent litigation with Purdue Pharma...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2009. Q3 2009 Summary --------------- - Total revenue...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors. Since October 2008, Dr. Claypool has been a Senior Partner at...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or the "Company") today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the...

- Third quarter financial results to be released November 4, 2009 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 26 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of...

Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer of the Company, is presenting at Rodman & Renshaw's 11th Annual Healthcare...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2009.Q2 2009 Summary --------------- - Finalized FDA...

- Second quarter financial results to be released July 29, 2009 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, July 20 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three months ended March 31, 2009.Q1 2009 Summary ---------------- - Received tentative U.S....

- First quarter financial results to be released on May 13, 2009 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 7 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2008.Fiscal 2008 Summary -------------------...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for CIP-TRAMADOL ER, the Company's extended-release...

- Fourth quarter and year end financial results to be released on February 18, 2009 - Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, Feb. 9 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2008.Q3 2008 Summary --------------- - Entered into a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it will now host its Q3 2008 conference call on Friday, November 7, 2008 at 10:00 a.m. (ET). Cipher invites all interested parties to...

Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer of the Company, will present a corporate update at Rodman & Renshaw's 10th Annual...

Cipher Pharmaceuticals Inc. (TSX: DND) announced that it has been informed that additional time will be required for the U.S. Food and Drug Administration to complete its review of the Company's...

- Third quarter financial results to be released on November 7, 2008 -Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 28 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has appointed John MacInnis as Vice President, Portfolio Development and Licensing. Mr. MacInnis will be responsible for identifying...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2008.Q2 2008 Summary --------------- - Submitted revised...

- Second quarter financial results to be released on Wednesday August 13, 2008 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Aug. 7 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that its revised New Drug Application (NDA) for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that the United States Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-ISOTRETINOIN, the Company's novel...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that a revised New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for CIP-TRAMADOL ER, its...